Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.</li><li>It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.</li><li>Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284, which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.</li></ul>

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284, which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.

LTRN: First Quarter 2025 Financial Results

<ul><li>Zacks Small-Cap Research Note for Lantern Pharma, Inc. (LTRN)</li></ul>

Zacks Small-Cap Research Note for Lantern Pharma, Inc. (LTRN)

<ul><li>Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.</li><li>It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.</li><li>Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.</li></ul>

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs.It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial.Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively.

United States

Lantern Pharma Inc. is a clinical stage biopharmaceutical company. The Company focuses on leveraging artificial intelligence, machine learning, and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies. Lantern Pharma operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lantern Pharma (LTRN US)

LTRN: First Quarter 2025 Financial Results

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for...

Zacks Small Cap Research

LTRN: IND Clearance for LP-184 in TNBC

Zacks Small-Cap Research Note for Lantern Pharma, Inc. (LTRN)

Zacks Small Cap Research

LTRN: 2024 Financial Results

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for...

Zacks Small Cap Research

LTRN: M&A Illuminates GBM Value

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for...

Zacks Small Cap Research

LTRN: Pediatric Rare Cancer in Focus

Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)